ARID1A and gastric cancer: According to our results, some common genetic mutations were identified in different metastatic patterns, and drug therapy might be suitable for stage IV GC treatment, such as PARP inhibitors for mutations of the KMT2 family and immunotherapy for ARID1A mutations.